Intellia Therapeutics (NTLA) Asset Utilization Ratio (2016 - 2026)
Intellia Therapeutics (NTLA) reported Asset Utilization Ratio of 0.08 for Q1 2026, up 97.25% year-over-year from 0.04 in Q1 2025, and up 7.82% on a QoQ basis from 0.08 in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Asset Utilization Ratio data on file, last reported at 0.08 in Q1 2026.
- Quarterly Asset Utilization Ratio rose 97.25% year-over-year to 0.08 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.08 (up 97.25% YoY) and the FY2025 annual result came in at 0.07, up 43.31% from the prior year.
- Asset Utilization Ratio advanced to 0.08 in Q1 2026 per NTLA's latest filing, from 0.08 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.08 in Q1 2026 and bottomed at 0.02 in Q1 2022.
- The 5-year median for Asset Utilization Ratio is 0.04 (2023), against an average of 0.05.
- Peak annual rise in Asset Utilization Ratio reached 136.33% in 2022, while the deepest fall reached 66.48% in 2022.
- Tracing NTLA's Asset Utilization Ratio over 5 years: stood at 0.04 in 2022, then declined by 28.75% to 0.03 in 2023, then soared by 71.69% to 0.05 in 2024, then surged by 56.41% to 0.08 in 2025, then rose by 7.82% to 0.08 in 2026.
- Per Business Quant, the three latest NTLA Asset Utilization Ratio figures stand at 0.08 (Q1 2026), 0.08 (Q4 2025), and 0.06 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.08 |
| Dec 31, 2025 | 0.08 |
| Sep 30, 2025 | 0.06 |
| Jun 30, 2025 | 0.06 |
| Mar 31, 2025 | 0.04 |
| Dec 31, 2024 | 0.05 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.04 |
| Mar 31, 2024 | 0.04 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.04 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.04 |
| Dec 31, 2022 | 0.04 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.03 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2021 | 0.02 |
| Sep 30, 2021 | 0.02 |
| Jun 30, 2021 | 0.06 |
| Mar 31, 2021 | 0.07 |
| Dec 31, 2020 | 0.09 |
| Sep 30, 2020 | 0.11 |
| Jun 30, 2020 | 0.11 |
| Mar 31, 2020 | 0.12 |
| Dec 31, 2019 | 0.13 |
| Sep 30, 2019 | 0.11 |
| Jun 30, 2019 | 0.11 |
| Mar 31, 2019 | 0.10 |
| Dec 31, 2018 | 0.09 |
| Sep 30, 2018 | 0.09 |
| Jun 30, 2018 | 0.08 |
| Mar 31, 2018 | 0.07 |
| Dec 31, 2017 | 0.08 |
| Sep 30, 2017 | 0.10 |
| Jun 30, 2017 | 0.08 |
| Mar 31, 2017 | 0.07 |
| Dec 31, 2016 | 0.05 |
| Sep 30, 2016 | 0.04 |
| Jun 30, 2016 | 0.05 |
| Mar 31, 2016 | 0.08 |